anti-depressants in palliative medicine
DESCRIPTION
Anti-depressants in Palliative Medicine. Rebecca Owen 24.10.12. Depression. Common in Palliative Care 15% meet criteria for major depressive disorder and many more experience depressive symptoms 1 Associated with: Increased pain/fatigue 1 Reduced t reatment adherence 1 - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Anti-depressants in Palliative Medicine](https://reader036.vdocuments.us/reader036/viewer/2022062422/568135cb550346895d9d2f4c/html5/thumbnails/1.jpg)
Anti-depressants in Palliative Medicine
Rebecca Owen24.10.12
![Page 2: Anti-depressants in Palliative Medicine](https://reader036.vdocuments.us/reader036/viewer/2022062422/568135cb550346895d9d2f4c/html5/thumbnails/2.jpg)
Depression
• Common in Palliative Care• 15% meet criteria for major depressive disorder and
many more experience depressive symptoms1
• Associated with:• Increased pain/fatigue1
• Reduced treatment adherence1
• Poorer prognosis1
• Higher mortality in range of physical illnesses1
![Page 3: Anti-depressants in Palliative Medicine](https://reader036.vdocuments.us/reader036/viewer/2022062422/568135cb550346895d9d2f4c/html5/thumbnails/3.jpg)
Pathophysiology
• Limbic and prefrontal cortex circuits regulate mood, attention, energy, appetite & sleep
• Adapt structurally and functionally to external stimuli (neuroplasticity)
• Impaired in depression• Complex interaction between neurotransmitter
availability and receptor regulation & sensitivity underlying affective symptoms.
![Page 4: Anti-depressants in Palliative Medicine](https://reader036.vdocuments.us/reader036/viewer/2022062422/568135cb550346895d9d2f4c/html5/thumbnails/4.jpg)
Involved Neurotransmitters
• Serotonin (5-HT) • Norepinephrine (NE)• Dopamine (DA)• Glutamate• Brain-derived neurotrophic factor (BDNF).
![Page 5: Anti-depressants in Palliative Medicine](https://reader036.vdocuments.us/reader036/viewer/2022062422/568135cb550346895d9d2f4c/html5/thumbnails/5.jpg)
Pharmacology 2
• Help restore impairment– Monoamines trigger release of nerve growth factors such as
BDNF
• Analgesic effect due to enhancement of mono-amine transmission by descending pain modulation pathway
– Can induce analgesia (NE and 5HT activity) and hyperalgesia (5HT activity)
![Page 6: Anti-depressants in Palliative Medicine](https://reader036.vdocuments.us/reader036/viewer/2022062422/568135cb550346895d9d2f4c/html5/thumbnails/6.jpg)
Beneficial and undesirable effects of antidepressants can vary because of:
• Mechanisms of action• Monoamines affected• Effect on other receptors• Pharmacokinetic profiles
![Page 7: Anti-depressants in Palliative Medicine](https://reader036.vdocuments.us/reader036/viewer/2022062422/568135cb550346895d9d2f4c/html5/thumbnails/7.jpg)
Predominant mechanism of Action2
![Page 8: Anti-depressants in Palliative Medicine](https://reader036.vdocuments.us/reader036/viewer/2022062422/568135cb550346895d9d2f4c/html5/thumbnails/8.jpg)
• Box 4e pcf 4
![Page 9: Anti-depressants in Palliative Medicine](https://reader036.vdocuments.us/reader036/viewer/2022062422/568135cb550346895d9d2f4c/html5/thumbnails/9.jpg)
Transporter and receptor affinities for selected antidepressants2
![Page 10: Anti-depressants in Palliative Medicine](https://reader036.vdocuments.us/reader036/viewer/2022062422/568135cb550346895d9d2f4c/html5/thumbnails/10.jpg)
Pharmacokinetic details for selected antidepressants2
![Page 11: Anti-depressants in Palliative Medicine](https://reader036.vdocuments.us/reader036/viewer/2022062422/568135cb550346895d9d2f4c/html5/thumbnails/11.jpg)
Suicide Risk and Antidepressants
• 1 in 1000 patients attempt suicide 6/12 after starting an anti-depressant
• If pt <25 yrs – can cause suicidal ideation and self harm (NNH 143)
– SSRIs > TCAs
• If pt >25 yrs – smaller increase in self harm (NNH 700), but no increase in suicidal ideation
– No difference between SSRIs and TCAs
![Page 12: Anti-depressants in Palliative Medicine](https://reader036.vdocuments.us/reader036/viewer/2022062422/568135cb550346895d9d2f4c/html5/thumbnails/12.jpg)
Epilepsy and Antidepressants
• Cause dose-dependent reduction in seizure threshold
• Lowest for SSRIs– Citalopram favoured (less interactions with other drugs)– Mirtazepine & Venlafaxine – less experience & data
• Higher risk with TCAs– Highest with Clomipramine, Bupropion & Maprotiline
• Can also cause seizures through hyponatraemia or alterations of anti-epileptic drug levels
![Page 13: Anti-depressants in Palliative Medicine](https://reader036.vdocuments.us/reader036/viewer/2022062422/568135cb550346895d9d2f4c/html5/thumbnails/13.jpg)
Parkinson’s Disease and Antidepressants
• SSRIs – can worsen extrapyramidal symptoms – serotonin reduces nigrostriatal dopamine release via
inhibitory 5HT2 receptors– Small risk (only few RCTs report any worsening)
• TCAs – Can worsen autonomic dysfunction (α blockade) & cognitive impairment (AChm blockade)
• SSRIs preferred to TCAs
![Page 14: Anti-depressants in Palliative Medicine](https://reader036.vdocuments.us/reader036/viewer/2022062422/568135cb550346895d9d2f4c/html5/thumbnails/14.jpg)
Serotonin Syndrome
• Results from ingestion of drugs which increase brain serotonin levels to cause:
– Autonomic hyperactivity– Neuromuscular activity– Altered mental status
• Onset rapid & progressive– Usually if 2nd serotoninergic drug reaches effective levels
• Essential features:– Clonus, agitation, sweating, tremor, hyperreflexia
![Page 15: Anti-depressants in Palliative Medicine](https://reader036.vdocuments.us/reader036/viewer/2022062422/568135cb550346895d9d2f4c/html5/thumbnails/15.jpg)
Drugs with serotoninergic potency 1
• Antidepressants – MAOIs – (all types)
• Antidepressants – SSRIs – (all types)
• Antidepressants – SNRIs– Clomipramine, Imipramine, Duloxetine, Milnacipran,
Venlafaxine
• Psychostimulants (serotonin releasers)– Dexamfetamine, MDMA (Ecstasy), (NOT METHYLPHENIDATE)
![Page 16: Anti-depressants in Palliative Medicine](https://reader036.vdocuments.us/reader036/viewer/2022062422/568135cb550346895d9d2f4c/html5/thumbnails/16.jpg)
Drugs with serotoninergic potency 2
• H1 antihistamines (serotonin re-uptake inhibitors
– Chlorphenamine, Brompheniramine
• Opioids (serotonin re-uptake inhibitors)– Fentanils, Methadone, Pethadine, Tramadol
• MAOIs– Furazolidone, Linezolid, Methylene blue, Procarbazine,
Selegiline
• SNRIs– Sibutramine
![Page 17: Anti-depressants in Palliative Medicine](https://reader036.vdocuments.us/reader036/viewer/2022062422/568135cb550346895d9d2f4c/html5/thumbnails/17.jpg)
Treatment of Serotonin Syndrome
• In severe cases, seek urgent advice from critical care specialist
– Rigidity, haemodynamic instability, temp > 38.5°C
• Discontinue causal meds• Supportive care (IV fluids, O2)• Symptomatice measures– BZD; agitation, myoclonus, seizures– 5HT2A antagonist; e.g. Chlorpromazine,
Olanzapine, Cyproheptadine
![Page 18: Anti-depressants in Palliative Medicine](https://reader036.vdocuments.us/reader036/viewer/2022062422/568135cb550346895d9d2f4c/html5/thumbnails/18.jpg)
Undesirable effects of SSRIs
• SSRIs + SNRIs decrease serotonin uptake from blood by platelets
• Therefore reduces overall levels in platelets• Adversely affects platelet aggregation• SSRIs triple the risk of GI bleeding
– If high risk patient – to consider use of NRI e.g. nortriptylline, mirtazepine
![Page 19: Anti-depressants in Palliative Medicine](https://reader036.vdocuments.us/reader036/viewer/2022062422/568135cb550346895d9d2f4c/html5/thumbnails/19.jpg)
Typical symptoms suggestive of depression
![Page 20: Anti-depressants in Palliative Medicine](https://reader036.vdocuments.us/reader036/viewer/2022062422/568135cb550346895d9d2f4c/html5/thumbnails/20.jpg)
Treatment of Mild Depression
![Page 21: Anti-depressants in Palliative Medicine](https://reader036.vdocuments.us/reader036/viewer/2022062422/568135cb550346895d9d2f4c/html5/thumbnails/21.jpg)
Treatment of Moderate Depression
![Page 22: Anti-depressants in Palliative Medicine](https://reader036.vdocuments.us/reader036/viewer/2022062422/568135cb550346895d9d2f4c/html5/thumbnails/22.jpg)
Treatment of Severe Depression
![Page 23: Anti-depressants in Palliative Medicine](https://reader036.vdocuments.us/reader036/viewer/2022062422/568135cb550346895d9d2f4c/html5/thumbnails/23.jpg)
Treatment resistant depression
![Page 24: Anti-depressants in Palliative Medicine](https://reader036.vdocuments.us/reader036/viewer/2022062422/568135cb550346895d9d2f4c/html5/thumbnails/24.jpg)
Short Prognosis
![Page 25: Anti-depressants in Palliative Medicine](https://reader036.vdocuments.us/reader036/viewer/2022062422/568135cb550346895d9d2f4c/html5/thumbnails/25.jpg)
Before starting antidepressant treatment
![Page 26: Anti-depressants in Palliative Medicine](https://reader036.vdocuments.us/reader036/viewer/2022062422/568135cb550346895d9d2f4c/html5/thumbnails/26.jpg)
Choice of Antidepressant
![Page 27: Anti-depressants in Palliative Medicine](https://reader036.vdocuments.us/reader036/viewer/2022062422/568135cb550346895d9d2f4c/html5/thumbnails/27.jpg)
Mirtazepine – Benefits
• Increase appetite• Reduce nausea• Sedative effect may be beneficial for some
patients• May have early onset of action, therefore a
good choice for patients with a short prognosis• Available as orodispersible tablet• Suitable in heart failure and diabetes
![Page 28: Anti-depressants in Palliative Medicine](https://reader036.vdocuments.us/reader036/viewer/2022062422/568135cb550346895d9d2f4c/html5/thumbnails/28.jpg)
Mirtazepine
Possible Side Effects• sedation• dizziness• constipation• hypertension• weight gain• oedema• orthostatic hypotension• dry mouth• fatigue, tremor• dizziness• confusion, anxiety• arthralgia, myalgia
Cautions• possible increased
serotonergic effects when given with tramadol or venlafaxine
• enhances anticoagulant effect of warfarin
![Page 29: Anti-depressants in Palliative Medicine](https://reader036.vdocuments.us/reader036/viewer/2022062422/568135cb550346895d9d2f4c/html5/thumbnails/29.jpg)
Sertraline
Benefits• Beneficial for renal
impairment• First choice for recent
cardiac event• Cautions• Risk of ventricular
arrhythmias if taken with droperidol
• Increased risk of bleeding when given with aspirin
Possible Side Effects• Nausea, vomiting, drowsiness,
dizziness, dry mouth, anorexia,dyspepsia, diarrhoea, insomnia, sweating, sexual dysfunction, agitation, hyponatraemia, pancreatitis, hepatitis, jaundice, liver failure, tachycardia, amnesia, paraesthesia, aggression, urinary incontinence, menstrual irregularities
![Page 30: Anti-depressants in Palliative Medicine](https://reader036.vdocuments.us/reader036/viewer/2022062422/568135cb550346895d9d2f4c/html5/thumbnails/30.jpg)
Citalopram
Benefits• Beneficial for agitated
depression/anxiety, nausea• Relatively safe for patients
at risk of seizures• Available as oral suspension• Cautions• Increased risk of bleeding
when given with aspirin• Possibly greater risk in
overdose than other SSRIs
Possible Side Effects• Nausea, vomiting, anorexia,
dyspepsia, diarrhoea, dry mouth,dizziness, insomnia, sweating, sexual dysfunction, agitation, hyponatraemia, palpitation, tachycardia, postural hypotension, confusion, impaired concentration, amnesia, migraine, paraesthesia, taste disturbance, increased salivation, rhinitis, tinnitus, polyuria, micturition disorders, euphoria, abnormal dreams
![Page 31: Anti-depressants in Palliative Medicine](https://reader036.vdocuments.us/reader036/viewer/2022062422/568135cb550346895d9d2f4c/html5/thumbnails/31.jpg)
Amitriptylline
Benefits• May be beneficial for patients with
insomnia or neuropathic pain• If a patient is already on a low dose
for neuropathic pain, it may be beneficial to increase this dose, rather than introduce another antidepressant
• May have an earlier onset of action than SSRIs
• There is evidence that TCAs are equally, if not more effective than SSRIs
• Cautions• Greater toxicity in overdose than
SSRIs
Possible Side Effects• Dry mouth, constipation,
hypotension, tachycardia, urinaryretention, confusion, dizziness, sleep disturbance, drowsiness, arrhythmia, abdominal pain, stomatitis, palpitation, oedema, restlessness, fatigue, mydraiasis, increased intra-ocular pressure, sexual dysfunction, nausea, sweating
![Page 32: Anti-depressants in Palliative Medicine](https://reader036.vdocuments.us/reader036/viewer/2022062422/568135cb550346895d9d2f4c/html5/thumbnails/32.jpg)
Physical disease contraindications of antidepressants 1
![Page 33: Anti-depressants in Palliative Medicine](https://reader036.vdocuments.us/reader036/viewer/2022062422/568135cb550346895d9d2f4c/html5/thumbnails/33.jpg)
Physical disease contraindications of antidepressants 2
![Page 34: Anti-depressants in Palliative Medicine](https://reader036.vdocuments.us/reader036/viewer/2022062422/568135cb550346895d9d2f4c/html5/thumbnails/34.jpg)
Physical disease contraindications of antidepressants 3
![Page 35: Anti-depressants in Palliative Medicine](https://reader036.vdocuments.us/reader036/viewer/2022062422/568135cb550346895d9d2f4c/html5/thumbnails/35.jpg)
Stopping Antidepressants
• Withdrawal syndrome can occur after abrupt cessation following >8 weeks of regular administration of antidepressant
• More common with drugs with shorter half lives– Most common with Paroxetine– Least common with fluoxetine
• Start within few days of stopping Rx• Resolve within 24 hrs of restarting Rx • Should progressively reduce over 4/52
![Page 36: Anti-depressants in Palliative Medicine](https://reader036.vdocuments.us/reader036/viewer/2022062422/568135cb550346895d9d2f4c/html5/thumbnails/36.jpg)
In Summary
• High prevalence of depression in palliative care
• Detecting depression is particularly challenging
– somatic symptoms, such as fatigue and insomnia, may be due to depression, advanced disease or medical treatment
– difficult to distinguish from normal fear and sadness which often accompany terminal illness
• Psychological therapy and antidepressant drugs are mainstay of treatment
![Page 37: Anti-depressants in Palliative Medicine](https://reader036.vdocuments.us/reader036/viewer/2022062422/568135cb550346895d9d2f4c/html5/thumbnails/37.jpg)
References
1. The Management of Depression in Palliative Care. European Clinical Guidelines 2010.
2. Palliative Care Formulary 4th Edition; Twycross & Wilcock 2011.